Sabine C. Linn

17.3k citations

231 papers · 9.1k indexed · 1 hit paper · h-index 48

Oncology top 0.5%
Cancer Research top 0.2%
Molecular Biology top 2%
Pulmonary and Respiratory Medicine top 0.5%
Genetics top 1%

Co-authors: Marc J. van de Vijver Michael Hauptmann Jelle Wesseling Karin Beelen Hugo M. Horlings Wilbert Zwart Emiel J. Rutgers Wolter J. Mooi
Topics: Breast Cancer Treatment Studies (84 papers)HER2/EGFR in Cancer Research (52 papers)Estrogen and related hormone effects (42 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Proceedings of the National Academy of Sciences The Lancet Nature Communications
Partner nations: Netherlands United States Germany

In The Last Decade

Sabine C. Linn

222 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

2007 1.2k citations Hugo M. Horlings, Karin Beelen et al. profile →

Peers

Countries citing papers authored by Sabine C. Linn

Since Specialization

Citations

This map shows the geographic impact of Sabine C. Linn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabine C. Linn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabine C. Linn more than expected).

Fields of papers citing papers by Sabine C. Linn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabine C. Linn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabine C. Linn. The network helps show where Sabine C. Linn may publish in the future.

Co-authorship network of co-authors of Sabine C. Linn

This figure shows the co-authorship network connecting the top 25 collaborators of Sabine C. Linn. A scholar is included among the top collaborators of Sabine C. Linn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabine C. Linn. Sabine C. Linn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort 2025 ·Breast Cancer Research and Treatment ·(unknown),Stefan Preković,Britt B.M. Suelmann,Janneke Verloop,Pieter J. Westenend,Sabine C. Linn,P. J. van Diest,Elsken van der Wall,Carmen van Dooijeweert	1
2	The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer 2023 ·JNCI Cancer Spectrum ·(unknown),Sandra M. E. Geurts,Irene E.G. van Hellemond,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Marjolein L. Smidt,Ingeborg J. H. Vriens,Vivianne C. G. Tjan‐Heijnen	4
3	Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial 2023 ·EClinicalMedicine ·Vivianne C. G. Tjan‐Heijnen,(unknown),Sandra M. E. Geurts,Ingeborg J. H. Vriens,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz	11
4	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial 2022 ·Journal of Clinical Oncology ·S.B. Vliek,Iris Noordhoek,Elma Meershoek‐Klein Kranenbarg,(unknown),Vincent O. Dezentjé,Agnes Jager,(unknown),Hein Putter,Annette W.G. van der Velden,Mathijs P. Hendriks,Sandra D. Bakker,Yvonne E A van Riet,Vivianne C. G. Tjan‐Heijnen,Johanneke E.A. Portielje,Judith R. Kroep,J.W.R. Nortier,Cornelis J.�H. van de Velde,Sabine C. Linn	8
5	Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols 2022 ·Human Reproduction ·Eva Balkenende,(unknown),C. C. M. Beerendonk,Kathrin Fleischer,Dominic Stoop,Annelies M. E. Bos,Cornelis B. Lambalk,R. Schats,J Smeenk,L Louwe,Astrid EP Cantineau,Jan Peter de Bruin,Sabine C. Linn,Fulco van der Veen,Madelon van Wely,Mariëtte Goddijn	24
6	FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer 2022 ·Cell Reports ·(unknown),Nalan Liv,(unknown),Mark Opdam,(unknown),(unknown),(unknown),Rutger C.C. Hengeveld,(unknown),Erik van Werkhoven,Harmjan R. Vos,Holger Rehmann,Boudewijn Burgering,Hendrika M. Oosterkamp,Susanne M.A. Lens,Judith Klumperman,Sabine C. Linn,Patrick W.B. Derksen	7
7	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer 2021 ·JNCI Cancer Spectrum ·Tessa G. Steenbruggen,Michael Schaapveld,Hugo M. Horlings,Joyce Sanders,(unknown),Esther H. Lips,Marie-Jeanne TFD Vrancken Peeters,Niels F. M. Kok,T. Wiersma,Laura J. Esserman,Laura van ‘t Veer,Sabine C. Linn,Sabine Siesling,Gabe S. Sonke	18
8	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients 2021 ·JNCI Journal of the National Cancer Institute ·(unknown),Katarzyna Jóźwiak,Gabe S. Sonke,Elsken van der Wall,P. J. van Diest,Sabine Siesling,Michael Hauptmann,Sabine C. Linn	5
9	The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers 2020 ·Molecular Cancer Research ·Irida Kastrati,Stacey E. P. Joosten,Svetlana E. Semina,(unknown),Svitlana D. Brovkovych,Joshua D. Stender,Hugo M. Horlings,Marleen Kok,Elaine T. Alarid,Geoffrey L. Greene,Sabine C. Linn,Wilbert Zwart,Jonna Frasor	38
10	PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane 2020 ·Journal of Cancer Research and Clinical Oncology ·(unknown),Mark Opdam,Vincent van der Noort,Joyce Sanders,(unknown),(unknown),Karin Beelen,Sabine C. Linn,Epie Boven	6
11	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017 2020 ·International Journal of Cancer ·Daniël J. van der Meer,Iris Kramer,Marissa C. van Maaren,P. J. van Diest,Sabine C. Linn,John H. Maduro,Luc J. A. Strobbe,Sabine Siesling,Marjanka K. Schmidt,Adri C. Voogd	51
12	Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas 2016 ·Cancer Research ·Marjolein Droog,Ekaterina Nevedomskaya,Yongsoo Kim,Tesa Severson,Koen D. Flach,Mark Opdam,Karianne Schuurman,Patrycja Gradowska,Michael Hauptmann,(unknown),Harry Hollema,Marian J.E. Mourits,Petra M. Nederlof,Hester van Boven,Sabine C. Linn,Lodewyk F.A. Wessels,Flora E. van Leeuwen,Wilbert Zwart	26
13	The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer 2016 ·Breast Cancer Research and Treatment ·Mette S. van Ramshorst,Margriet van der Heiden‐van der Loo,(unknown),Sabine C. Linn,Gabe S. Sonke	27
14	High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1 -like Breast Cancer 2015 ·Molecular Cancer Therapeutics ·Philip C. Schouten,Marieke A. Vollebergh,Mark Opdam,(unknown),Martin Lodén,Jelle Wesseling,Michael Hauptmann,Sabine C. Linn	43
15	DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial. 2015 ·Journal of Clinical Oncology ·Laura van’t Veer,Laura Esserman,Ashish Sanil,Annuska M. Glas,(unknown),Sabine C. Linn,Lamorna Brown Swigart,Gillian L. Hirst,(unknown),Olufunmilayo I. Olopade,Hope S. Rugo,Don Berry,Denise M. Wolf,Christina Yau	1
16	Breast Cancers with a BRCA1 -like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy 2014 ·Clinical Cancer Research ·Philip C. Schouten,Frederik Marmé,Sebastian Aulmann,Hans‐Peter Sinn,Hendrik F. van Essen,Bauke Ylstra,Michael Hauptmann,Andreas Schneeweiß,Sabine C. Linn	30
17	Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer 2013 ·Cancer Research ·Maurice P.H.M. Jansen,Theo Knijnenburg,(unknown),Iris Simón,Ron Kerkhoven,Marjolein Droog,Arno Velds,Steven Van Laere,Luc Dirix,Xanthippi Alexi,John A. Foekens,Lodewyk F.A. Wessels,Sabine C. Linn,Els M.J.J. Berns,Wilbert Zwart	57
18	Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans 2003 ·American Journal Of Pathology ·Sabine C. Linn,Robert B. West,Jonathan R. Pollack,Shirley Zhu,Tina Hernandez‐Boussard,Torsten O. Nielsen,Brian P. Rubin,Rajiv M. Patel,John R. Goldblum,David Siegmund,David Botstein,Patrick O. Brown,C. Blake Gilks,Matt van de Rijn	107
19	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy 1997 ·International Journal of Cancer ·Sabine C. Linn,Herbert M. Pinedo,J van Ark-Otte,Paul van der Valk,Klaas Hoekman,Aafke H. Honkoop,Jan B. Vermorken,Giuseppe Giaccone	7
20	A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. 1997 ·PubMed ·N Feller,Klaas Hoekman,Catharina M. Kuiper,Sabine C. Linn,Henk M.W. Verheul,B.G. Wolthers,C. Popp‐Snijders,Herbert M. Pinedo	9

About Sabine C. Linn

Sabine C. Linn is a scholar working on Cancer Research, Oncology and Genetics, having authored 231 papers that have together received 9.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (84 papers), HER2/EGFR in Cancer Research (52 papers) and Estrogen and related hormone effects (42 papers). The work is most often cited by research in Cancer Research (3.4k citations), Oncology (4.7k citations) and Pulmonary and Respiratory Medicine (2.4k citations). Sabine C. Linn has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Marc J. van de Vijver, Michael Hauptmann, Jelle Wesseling, Karin Beelen, Hugo M. Horlings, Wilbert Zwart, Emiel J. Rutgers, Wolter J. Mooi, Ralph Meuwissen and Anton Berns. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact